Description: ABT-510 TFA, the trifluoroacetic acid (TFA) salt form of ABT-510 which is a TSP-1 mimetic drug, is a synthetic peptide
composed of nine-amino acids, it acts by mimicking the anti-angiogenic
activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510
inhibits the actions of several pro-angiogenic growth factors important
to tumor neovascularization; these pro-angiogenic growth factors include
vascular endothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8
(IL-8). ABT-510 was designed with TSRs as base, displayed
anti-angiogenic properties in a phase 1 clinical trial in newly
diagnosed glioblastoma.
References:
1. SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma. Oncotarget. 2017 Sep 12;8(49):85969-85983.
2. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia. 2010 Mar;12(3):275-83.